Ayman Youssef
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ayman Youssef has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ata Ur Rehman
Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
1 shared publication - Hagar Bessar
Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication - Jatin Roper
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA, duke.edu
1 shared publication - Jörn Karhausen
Department of Anesthesiology, Duke University Medical Center, Durham, USA
1 shared publication - Luis Ulloa
Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
1 shared publication Mohamed AbdElkader Teama
Department of Dermatology, Venereology and Andrology Faculty of Medicine Zagazig University Zagazig Egypt
1 shared publication
Latest Publications
- 20 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (774) , eadl2184
Vagal stimulation ameliorates murine colitis by regulating SUMOylation
Inflammatory bowel diseases (IBDs) are chronic debilitating conditions without cure, the etiologies of which are unknown, that shorten the lifespans of 7 million patients worldwide by nearly 10%. Here, we found that decreased autonomic parasympathetic tone resulted in increased IBD susceptibility and mortality in mouse models of disease. Conversely, vagal stimulation restored neuromodulation and ameliorated colitis by inhibiting the posttranslational modification SUMOylation through a mechanism independent of the canonical interleukin-10/α7 nicotinic cholinergic vagal pathway. Colonic biopsies from patients with IBDs and mouse models showed an increase in small ubiquitin-like modifier (SUMO)2 and SUMO3 during active disease. In global genetic knockout mouse models, the deletion of Sumo3 protected against development of colitis and delayed onset of disease, whereas deletion of Sumo1 halted the progression of colitis. Bone marrow transplants from Sumo1 -knockout (KO) but not Sumo3 -KO mice into wild-type mice conferred protection against development of colitis. Electric stimulation of the cervical vagus nerve before the induction of colitis inhibited SUMOylation and delayed the onset of colitis in Sumo1 -KO mice and resulted in milder symptoms in Sumo3 -KO mice. Treatment with TAK-981, a first-in-class inhibitor of the SUMO-activating enzyme, ameliorated disease in three murine models of IBD and reduced intestinal permeability and bacterial translocation in a severe model of the disease, suggesting the potential to reduce progression to sepsis. These results reveal a pathway of vagal neuromodulation that reprograms endogenous stress-adaptive responses through inhibition of SUMOylation and suggest SUMOylation as a therapeutic target for IBD.
- 20 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (774) , eadl2184
Vagal stimulation ameliorates murine colitis by regulating SUMOylation
Inflammatory bowel diseases (IBDs) are chronic debilitating conditions without cure, the etiologies of which are unknown, that shorten the lifespans of 7 million patients worldwide by nearly 10%. Here, we found that decreased autonomic parasympathetic tone resulted in increased IBD susceptibility and mortality in mouse models of disease. Conversely, vagal stimulation restored neuromodulation and ameliorated colitis by inhibiting the posttranslational modification SUMOylation through a mechanism independent of the canonical interleukin-10/α7 nicotinic cholinergic vagal pathway. Colonic biopsies from patients with IBDs and mouse models showed an increase in small ubiquitin-like modifier (SUMO)2 and SUMO3 during active disease. In global genetic knockout mouse models, the deletion of Sumo3 protected against development of colitis and delayed onset of disease, whereas deletion of Sumo1 halted the progression of colitis. Bone marrow transplants from Sumo1 -knockout (KO) but not Sumo3 -KO mice into wild-type mice conferred protection against development of colitis. Electric stimulation of the cervical vagus nerve before the induction of colitis inhibited SUMOylation and delayed the onset of colitis in Sumo1 -KO mice and resulted in milder symptoms in Sumo3 -KO mice. Treatment with TAK-981, a first-in-class inhibitor of the SUMO-activating enzyme, ameliorated disease in three murine models of IBD and reduced intestinal permeability and bacterial translocation in a severe model of the disease, suggesting the potential to reduce progression to sepsis. These results reveal a pathway of vagal neuromodulation that reprograms endogenous stress-adaptive responses through inhibition of SUMOylation and suggest SUMOylation as a therapeutic target for IBD.
- 4 January 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (9) , 2940-2944
Serum angiopoietin‐2 level as a novel potential biomarker in oral lichen planus
Background: Lichen planus is a common chronic cutaneous inflammatory disease. Recent advances evidenced that angiogenesis is tightly connected to it. More recently, the endothelial specific growth factor angiopoietin‐2 has been clarified to interact with vascular endothelial growth factor. Angiopoietin‐2 level has not been investigated in lichen planus.Aim: To evaluate serum level of angiopoietin‐2 in cutaneous and oral lichen planus.Methods: Ninety patients were investigated, 45 patients with lichen planus. In addition to forty‐five healthy control, the activity of the disease was estimated at the time of examination. The serum level of angiopoietin‐2 had been estimated by enzyme‐linked immunosorbent assay. The relationships between angiopoietin‐2 serum level and disease severity, type of lichen, and visual analogue scale score (VAS) were determined.Results: The serum levels of angiopoietin‐2 were substantially higher in patients with both cutaneous and oral lesions than patients with cutaneous lichen planus only (P < .001).Conclusions: Serum angiopoietin‐2 is elevated in patients compared with normal subjects and is correlated with the presence of oral lesions and disease severity, that reflects its role in angiogenesis and inflammation, and angiopoietin‐2 serum level could be a potential marker for monitoring the oral lichen to identify possible malignant transformation.
- 4 January 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (9) , 2940-2944
Serum angiopoietin‐2 level as a novel potential biomarker in oral lichen planus
Background: Lichen planus is a common chronic cutaneous inflammatory disease. Recent advances evidenced that angiogenesis is tightly connected to it. More recently, the endothelial specific growth factor angiopoietin‐2 has been clarified to interact with vascular endothelial growth factor. Angiopoietin‐2 level has not been investigated in lichen planus.Aim: To evaluate serum level of angiopoietin‐2 in cutaneous and oral lichen planus.Methods: Ninety patients were investigated, 45 patients with lichen planus. In addition to forty‐five healthy control, the activity of the disease was estimated at the time of examination. The serum level of angiopoietin‐2 had been estimated by enzyme‐linked immunosorbent assay. The relationships between angiopoietin‐2 serum level and disease severity, type of lichen, and visual analogue scale score (VAS) were determined.Results: The serum levels of angiopoietin‐2 were substantially higher in patients with both cutaneous and oral lesions than patients with cutaneous lichen planus only (P < .001).Conclusions: Serum angiopoietin‐2 is elevated in patients compared with normal subjects and is correlated with the presence of oral lesions and disease severity, that reflects its role in angiogenesis and inflammation, and angiopoietin‐2 serum level could be a potential marker for monitoring the oral lichen to identify possible malignant transformation.
- 1 June 2019
- Published by Elsevier in Human Immunology
- Vol. 80 (6) , 393-399
B cells in chronic graft-versus-host disease
- 1 June 2019
- Published by Elsevier in Human Immunology
- Vol. 80 (6) , 393-399
B cells in chronic graft-versus-host disease